Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06720597 · ClinicalTrials.gov registry record · NA
EndoPAT Device for Endothelial Dysfunction in ED
A NA study of Endothelial Dysfunction and Erectile Dysfunction, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06720597: Recruiting NA study of Endothelial Dysfunction and Erectile Dysfunction, sponsored by University of California, Irvine.
NCT06720597 is a NA study of Endothelial Dysfunction and Erectile Dysfunction that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 120 participants, above the 90-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06720597, a NA study of Endothelial Dysfunction and Erectile Dysfunction, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy
Primary Outcome
Definition: RHI is a measure of endothelial function derived from the EndoPAT device, which assesses the endothelium's ability to respond to induced hyperemia. Measurement: RHI is calculated based on the changes in digital pulse volume during reactive hyperemia following a 5-minute arterial occlusion. Criteria for Evaluation: Baseline RHI: Measured before any intervention. Post-Intervention RHI: Measured at 3 months and 6 months post-intervention. Improvement in RHI: Defined as an increase in
Conditions Studied
Interventions
- DRUG Daily low-dose PDE5 inhibitor therapy
- DRUG Testosterone therapy as per clinical guidelines.
Study Locations (1)
California
- UCI Urology | Men's Health Center - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2027-01 |
| Phase | NA |
What NCT06720597 shows while recruiting
NCT06720597 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 90-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (33% higher).
The record links to 3 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Daily low-dose PDE5 inhibitor therapy is the first listed.
NCT06720597 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06720597 about?
NCT06720597 is a clinical study titled "EndoPAT Device for Endothelial Dysfunction in ED". To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endo...
What is the current status of trial NCT06720597?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-08-13. Estimated completion is 2027-01.
What conditions does trial NCT06720597 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Erectile Dysfunction, Hypogonadism, Male.
What interventions are being tested in trial NCT06720597?
The interventions under investigation include: Daily low-dose PDE5 inhibitor therapy (DRUG), Testosterone therapy as per clinical guidelines. (DRUG).
Who is sponsoring clinical trial NCT06720597?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06720597 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06720597's enrollment target sits among peer trials
120 8th of 45 higher than 38 of 45 other Endothelial Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endothelial Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
ACEs, SIRT1, and Premature Vascular Aging in Humans
RECRUITING · NA
-
Sodium Lowering Vascular Effects Trial
RECRUITING · NA
-
NightWare and Cardiovascular Health in Veterans With PTSD
RECRUITING · NA
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
-
Microvascular Dysfunction in Obesity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI